Search results for "antibody"

Article Elucidating Biosimilars Characterization
Compare this compound with the monoclonal antibody trastuzumab, which has a reported chemical formula of C6470H10012N1726O2013S42 and a molecular weight of 145531.50 g/mol, approximately 260 times the…

Article Best Practices for Selecting a Top-Quality Cell Line
“A balanced plasmid ratio usually has dramatic impact on some formats of bispecific antibody cell line development to minimize impurities,” she explains. Factors such as cell growth and metabolism, as…

Article Improving Process-Scale Chromatography
The development of new resin chemistries including enhancements to Protein A for monoclonal antibody (mAb) capture, increasing use of automation, implementation of single-use technologies, and explora…

Article Analysis of Glycosylation in Biosimilars
This compares the MS traces of the N-glycans released from two different glycoproteins: a classic antibody and a secretory glycoprotein. Antibodies produce glycans that are relatively small and simple…

Article Implications of Cell Culture Conditions on Protein Glycosylation
Figure 1: Graphic showing IgG antibody structure, sites for glycosylation, and potential variability. Proteins are delicate molecules compared with small-molecule drugs and present multiple stabili…

Article Ligand-Binding Assays and the Determination of Biosimilarity
…lecule are involved in binding with different activities (the Fab and Fc regions, which bind to the antibody target/ligand and Fc receptors [CD64, CD32, CD16, and FcRN], respectively). While in-vitro…

Article Trends in BioPharma Approvals in 2013
Engineered antibodies Genentech’s Gazyva represents another milestone in antibody approvals, being the first glycoengineered mAb to come on the market in the US. mAbs are glycoproteins, carrying a…

Article ADC Development Robust Despite Lackluster Performance
The ADC construct combines a targeted monoclonal antibody (mAb) with a cytotoxic agent, linked together with a stable linker technology. An ADC enables the specific delivery of chemotherapeutics to tu…

Article Patenting Prospects for Cell-Based Therapies
For example, in the Federal Circuit decision, In re Alonso (11), the claimed invention was directed to antibody reagents and methods for treating neurofibrosarcomas using a monoclonal antibody idiotyp…

Article Biopharma in 2015: A Year for Approvals and Innovations
Immediately following its acquisition by Pfizer, Hospira announced a major milestone in February, 2015: its first monoclonal antibody (mAb) biosimilar was approved for use in West Europe.2 And in Nove…

Previous PageNext Page